KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $5.9 million.

  • Adaptive Biotechnologies' Change in Accured Expenses rose 1009322.03% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 11557.85%. This contributed to the annual value of $671000.0 for FY2024, which is 11240.98% up from last year.
  • Adaptive Biotechnologies' Change in Accured Expenses amounted to $5.9 million in Q3 2025, which was up 1009322.03% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Change in Accured Expenses registered a high of $10.5 million during Q4 2022, and its lowest value of -$15.9 million during Q1 2023.
  • For the 5-year period, Adaptive Biotechnologies' Change in Accured Expenses averaged around $306052.6, with its median value being $407000.0 (2024).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 15071.34% in 2023, then surged by 1009322.03% in 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Change in Accured Expenses (Quarter) stood at -$1.6 million in 2021, then skyrocketed by 767.3% to $10.5 million in 2022, then plummeted by 49.3% to $5.3 million in 2023, then fell by 20.13% to $4.3 million in 2024, then skyrocketed by 38.27% to $5.9 million in 2025.
  • Its Change in Accured Expenses was $5.9 million in Q3 2025, compared to $3.3 million in Q2 2025 and -$9.7 million in Q1 2025.